Q3 2024 Earnings Call Transcript November 5, 2024 Rhythm Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $-0.73, expectations were $-0.8. Operator: Good day, and thank you for ...

Third Quarter 2024 Results Key Financial Results Revenue: US$33.3m (up 48% ...

Even though Agios Pharmaceuticals, Inc. ( NASDAQ:AGIO ) posted strong earnings recently, the stock hasn't reacted in ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $62.5, a high ...

Enticed by a reward of $1 million, a former police officer helped a foreign scam syndicate use Singapore as a conduit to ...

Investigations revealed that a French pharmaceutical company fell victim to a business e-mail impersonation scam by the syndicate in March 2020. The firm transferred more than $10 million for what ...

Ultragenyx Pharmaceutical RARE during the recent three months, expressing a mix of bullish and bearish perspectives. The table below provides a snapshot of their recent ratings, showcasing how ...

Reports Q3 revenue $175.7M, consensus $157.3M. The company said, “For the third quarter and first nine months of 2024, strong performance ...

英为财情Investing.com - Supernus Pharmaceuticals (NASDAQ: SUPN)星期一发布了第三季度的财报，数据显示，公司营收高于分析师的预期，每股收益超出了分析师的预期。 在该公司发布的最新财报中，公司每股收益为$0.69，总营收为$175.69M，而此前英为财情Investing.com对分析师的调查显示，分析师预期该公司的营收为$157.3M，每股收益为 ...

Stifel Nicolaus analyst Annabel Samimy maintained a Buy rating on Viking Therapeutics (VKTX – Research Report) today and set a price ...

The drugmaker posted revenue of $117.1 million in the period, surpassing Street forecasts. Three analysts surveyed by Zacks expected $114.8 million. BioCryst expects full-year revenue in the range of ...